Compound ID | 2896
Class: Pleuromutilin
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, vancomycin-resistant Enterococcus faecium |
| Propensity to select resistant mutants: | Yes, at 6 to 4.4 x 10^9 mutation frequency at 4xMIC |
| Description: | Semisynthetic compound with triaromatic C22-conjugated pleuromutilin scaffold; efficacious in reducing Staphylococcus aureus burden in a mouse infection model; oral solution and current form (2 HCl) makes bioavailability of compound unfavourable (likely poor intestinal solubility or high metabolism in mice and pigs); derivatives reported |
| Institute where first reported: | Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, DK-5230 Odense M, Denmark |
| Year first mentioned: | 2024 |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/168841449 |
| Guide to Pharmacology: | compound 16 [PMID: 38385364] |
| Citation: | https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02153 |